Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

(Johns Hopkins Medicine) Researchers at Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine have developed an integrated genomic approach that potentially could help physicians predict which patients with non-small cell lung cancer will respond to therapy with immune checkpoint inhibitors.